{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:03:13Z","timestamp":1790136193329,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40121-019-00259-4","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:39:51Z","timestamp":1565224791000},"page":"671-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Cefazolin Versus Anti-Staphylococcal Penicillins for the Treatment of Patients with Methicillin-Susceptible Staphylococcus aureus Infection: A Meta-Analysis with Trial Sequential Analysis"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0033-4508","authenticated-orcid":false,"given":"John M.","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lolade","family":"Bakare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Casapao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Klinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey M.","family":"Childs-Kean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel F.","family":"Pomputius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,8]]},"reference":[{"issue":"4","key":"259_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ijantimicag.2011.05.013","volume":"38","author":"H Hanberger","year":"2011","unstructured":"Hanberger H, Walther S, Leone M, Barie PS, Rello J, Lipman J, et al. Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents. 2011;38(4):331\u20135.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"259_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/CMR.05022-11","volume":"25","author":"SJ van Hal","year":"2012","unstructured":"van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012;25(2):362\u201386.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"259_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/cid\/civ308","volume":"61","author":"JS McDanel","year":"2015","unstructured":"McDanel JS, Perencevich EN, Diekema DJ, Herwaldt LA, Smith TC, Chrischilles EA, et al. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015;61(3):361\u20137.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"259_CR4","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1086\/379021","volume":"37","author":"EC Nannini","year":"2003","unstructured":"Nannini EC, Singh KV, Murray BE. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin Infect Dis. 2003;37(9):1194\u20138.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"259_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10096-014-2241-5","volume":"34","author":"YP Chong","year":"2015","unstructured":"Chong YP, Park SJ, Kim ES, Bang KM, Kim MN, Kim SH, et al. Prevalence of blaZ gene types and the cefazolin inoculum effect among methicillin-susceptible Staphylococcus aureus blood isolates and their association with multilocus sequence types and clinical outcome. Eur J Clin Microbiol Infect Dis. 2015;34(2):349\u201355.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"259_CR6","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med."},{"issue":"6","key":"259_CR7","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/bcp.13554","volume":"84","author":"JP Rindone","year":"2018","unstructured":"Rindone JP, Mellen CK. Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia. Br J Clin Pharmacol. 2018;84(6):1258\u201366.","journal-title":"Br J Clin Pharmacol"},{"key":"259_CR8","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"issue":"3","key":"259_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SY Tong","year":"2015","unstructured":"Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603\u201361.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"259_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","volume":"17","author":"J Wetterslev","year":"2017","unstructured":"Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17(1):39.","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"259_CR11","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","volume":"29","author":"MB Mathur","year":"2018","unstructured":"Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Website and R package for computing E-values. Epidemiology. 2018;29(5):e45\u20137.","journal-title":"Epidemiology"},{"issue":"4","key":"259_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"12","key":"259_CR13","doi-asserted-by":"publisher","first-page":"E184","DOI":"10.1002\/phar.2052","volume":"37","author":"A Algrim","year":"2017","unstructured":"Algrim A, Twilla J, Samarin M, Cummings C. Comparison of nafcillin and cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia. Pharmacotherapy. 2017;37(12):E184. https:\/\/doi.org\/10.1002\/phar.2052.","journal-title":"Pharmacotherapy."},{"issue":"5","key":"259_CR14","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/jac\/dku560","volume":"70","author":"AD Bai","year":"2015","unstructured":"Bai AD, Showler A, Burry L, Steinberg M, Ricciuto DR, Fernandes T, et al. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study. J Antimicrob Chemother. 2015;70(5):1539\u201346.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"259_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000499033","volume":"63","author":"CC Burrelli","year":"2019","unstructured":"Burrelli CC, Broadbent EK, Margulis A, Snyder GM, Gold HS, McCoy C, et al. Does the beta-lactam matter? Nafcillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bloodstream infections. Chemotherapy. 2019;63(6):345\u201351.","journal-title":"Chemotherapy"},{"issue":"2","key":"259_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ijantimicag.2018.02.013","volume":"52","author":"JS Davis","year":"2018","unstructured":"Davis JS, Turnidge J, Tong S. A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2018;52(2):297\u2013300.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"259_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40121-017-0148-z","volume":"6","author":"LK Flynt","year":"2017","unstructured":"Flynt LK, Kenney RM, Zervos MJ, Davis SL. The safety and economic impact of cefazolin versus nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections. Infect Dis Ther. 2017;6(2):225\u201331.","journal-title":"Infect Dis Ther."},{"issue":"11","key":"259_CR18","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1128\/AAC.00485-11","volume":"55","author":"S Lee","year":"2011","unstructured":"Lee S, Choe PG, Song KH, Park SW, Kim HB, Kim NJ, et al. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia? Antimicrob Agents Chemother. 2011;55(11):5122\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"259_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cmi.2017.07.001","volume":"24","author":"S Lee","year":"2018","unstructured":"Lee S, Song KH, Jung SI, Park WB, Lee SH, Kim YS, et al. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea. Clin Microbiol Infect. 2018;24(2):152\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"259_CR20","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1128\/AAC.02800-14","volume":"58","author":"J Li","year":"2014","unstructured":"Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS 2nd. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58(9):5117\u201324.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"259_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/cid\/cix287","volume":"65","author":"JS McDanel","year":"2017","unstructured":"McDanel JS, Roghmann MC, Perencevich EN, Ohl ME, Goto M, Livorsi DJ, et al. Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus Infections complicated by bacteremia: a Nationwide Cohort Study. Clin Infect Dis. 2017;65(1):100\u20136.","journal-title":"Clin Infect Dis"},{"key":"259_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2018.07.006","author":"MA Miller","year":"2018","unstructured":"Miller MA, Fish DN, Barber GR, Barron MA, Goolsby TA, Moine P, et al. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections. J Microbiol Immunol Infect. 2018. https:\/\/doi.org\/10.1016\/j.jmii.2018.07.006(Epub ahead of print).","journal-title":"J Microbiol Immunol Infect."},{"issue":"5","key":"259_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jiph.2018.02.004","volume":"11","author":"ML Monogue","year":"2018","unstructured":"Monogue ML, Ortwine JK, Wei W, Eljaaly K, Bhavan KP. Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia. J Infect Public Health. 2018;11(5):727\u201331.","journal-title":"J Infect Public Health."},{"issue":"10","key":"259_CR24","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","volume":"17","author":"M Paul","year":"2011","unstructured":"Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect. 2011;17(10):1581\u20136.","journal-title":"Clin Microbiol Infect"},{"key":"259_CR25","unstructured":"Phe K, Russo HR. Comparing Clinical Outcomes in Patients Treated With Cefazolin Versus Nafcillin for Methicillin Susceptible Staphylococcus aureus Bacteremia Secondary to High-Inoculum Infections [abstract]. In: Proceedings of the 55th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 2015 Sept 17-21; San Diego, CA. ICAAC; 2015. https:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=f8c4b522-bc42-4501-a27f-91fd36a2fa47&cKey=68acf0cb-7963-4529-832e-913fd324bd98&mKey=7a574a80-eab1-4b50-b343-4695df14907e. Accessed 14 June 2019."},{"issue":"8","key":"259_CR26","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1128\/AAC.00243-16","volume":"60","author":"S Pollett","year":"2016","unstructured":"Pollett S, Baxi SM, Rutherford GW, Doernberg SB, Bacchetti P, Chambers HF. Cefazolin versus nafcillin for methicillin-sensitive Staphylococcus aureus bloodstream infection in a california tertiary medical center. Antimicrob Agents Chemother. 2016;60(8):4684\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"259_CR27","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1128\/AAC.04677-14","volume":"59","author":"SN Rao","year":"2015","unstructured":"Rao SN, Rhodes NJ, Lee BJ, Scheetz MH, Hanson AP, Segreti J, et al. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2015;59(9):5232\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"259_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1542-4758.2010.00507.x","volume":"15","author":"CJ Renaud","year":"2011","unstructured":"Renaud CJ, Lin X, Subramanian S, Fisher DA. High-dose cefazolin on consecutive hemodialysis in anuric patients with Staphylococcal bacteremia. Hemodial Int. 2011;15(1):63\u20138.","journal-title":"Hemodial Int."},{"key":"259_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/1471-2334-11-279","volume":"11","author":"ML Schweizer","year":"2011","unstructured":"Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011;11:279.","journal-title":"BMC Infect Dis"},{"key":"259_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2124","author":"MD Shah","year":"2018","unstructured":"Shah MD, Wardlow LC, Stevenson KB, Coe KE, Reed EE. Clinical outcomes with penicillin versus alternative beta-lactams in the treatment of penicillin-susceptible Staphylococcus aureus bacteremia. Pharmacotherapy. 2018. https:\/\/doi.org\/10.1002\/phar.2124(Epub ahead of print).","journal-title":"Pharmacotherapy."},{"issue":"3","key":"259_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/cid\/ciu301","volume":"59","author":"I Youngster","year":"2014","unstructured":"Youngster I, Shenoy ES, Hooper DC, Nelson SB. Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting. Clin Infect Dis. 2014;59(3):369\u201375.","journal-title":"Clin Infect Dis"},{"issue":"Suppl","key":"259_CR32","doi-asserted-by":"publisher","first-page":"S386","DOI":"10.1093\/infdis\/128.Supplement_2.S386","volume":"128","author":"EL Quinn","year":"1973","unstructured":"Quinn EL, Pohlod D, Madhavan T, Burch K, Fisher E, Cox F. Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. J Infect Dis. 1973;128(Suppl):S386\u20139.","journal-title":"J Infect Dis"},{"issue":"7","key":"259_CR33","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","volume":"25","author":"S Weis","year":"2019","unstructured":"Weis S, Kesselmeier M, Davis JS, Morris AM, Lee S, Scherag A, et al. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteremia: a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(7):818\u201327.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"259_CR34","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1093\/jac\/dky259","volume":"73","author":"MR Bidell","year":"2018","unstructured":"Bidell MR, Patel N, O\u2019Donnell JN. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. J Antimicrob Chemother. 2018;73(10):2643\u201351.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"259_CR35","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s12879-018-3418-9","volume":"18","author":"C Shi","year":"2018","unstructured":"Shi C, Xiao Y, Zhang Q, Li Q, Wang F, Wu J, et al. Efficacy and safety of cefazolin versus anti Staphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis. BMC Infect Dis. 2018;18(1):508.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"259_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ijantimicag.2018.11.013","volume":"53","author":"BJ Lee","year":"2019","unstructured":"Lee BJ, Wang SK, Constantino-Corpuz JK, Apolinario K, Nadler B, McDanel JS, et al. Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections in acutely ill adult patients: Results of a systematic review and meta-analysis. Int J Antimicrob Agents. 2019;53(3):225\u201333.","journal-title":"Int J Antimicrob Agents."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-019-00259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-019-00259-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-019-00259-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T02:26:29Z","timestamp":1715653589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-019-00259-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,8]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["259"],"URL":"https:\/\/doi.org\/10.1007\/s40121-019-00259-4","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,8]]},"assertion":[{"value":"14 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}